Affinage

AGPAT2

1-acyl-sn-glycerol-3-phosphate acyltransferase beta · UniProt O15120

Length
278 aa
Mass
30.9 kDa
Annotated
2026-04-28
44 papers in source corpus 14 papers cited in narrative 14 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

AGPAT2 is an endoplasmic reticulum-localized acyltransferase that catalyzes the conversion of lysophosphatidic acid (LPA) to phosphatidic acid (PA), a central branch-point intermediate for glycerophospholipid and triacylglycerol biosynthesis, and is essential for adipocyte differentiation and survival (PMID:11967537, PMID:37752957). AGPAT2 forms functional complexes with CDP-diacylglycerol synthases (CDS1/2) to channel PA into the CDP-DAG phospholipid pathway and is scaffolded by seipin dodecamers together with lipin 1 and GPAT3 during adipogenesis; loss of AGPAT2 paradoxically causes PA accumulation by destabilizing CDS enzymes, impairing PI3K/Akt and PPARγ signaling and driving hepatic insulin resistance through accumulation of specific PA species that upregulate gluconeogenic enzymes (PMID:34824276, PMID:25737955, PMID:22872237, PMID:24425876). AGPAT2-generated PA also supplies the dynamin-related GTPase DRP1 to promote ER tubulation, and AGPAT2 knockout shifts ER morphology from tubules to sheets (PMID:41387688). Loss-of-function mutations in AGPAT2 cause congenital generalized lipodystrophy type 1 (CGL1) (PMID:11967537).

Mechanistic history

Synthesis pass · year-by-year structured walk · 11 steps
  1. 2002 High

    Identification of AGPAT2 as the LPA-to-PA acyltransferase whose loss causes CGL1 established both its enzymatic function and its essential role in adipose tissue development.

    Evidence Genetic linkage mapping, mutation identification, and biochemical characterization in CGL families

    PMID:11967537

    Open questions at the time
    • Mechanism by which loss of AGPAT2 prevents fat formation was unknown
    • In vivo consequences beyond lipodystrophy not characterized
  2. 2009 High

    The Agpat2-null mouse recapitulated human CGL1 and revealed compensatory activation of an alternative monoacylglycerol pathway (via MOGAT1) and massive hepatic de novo lipogenesis, showing that AGPAT2 loss triggers systemic metabolic rewiring beyond adipose tissue.

    Evidence Agpat2 knockout mouse model with gene expression analysis and lipid metabolic flux measurements

    PMID:19187773

    Open questions at the time
    • Signaling pathways downstream of AGPAT2 loss in adipocytes not yet defined
    • Whether hepatic steatosis reflects local or systemic AGPAT2 deficiency was unresolved
  3. 2011 High

    Hepatic overexpression of AGPAT2 failed to rescue steatosis in Agpat2-null mice, establishing that liver fat accumulation is secondary to adipose tissue loss and insulin resistance rather than a cell-autonomous hepatic defect.

    Evidence In vitro substrate specificity assays, structural modeling, adenoviral liver-specific overexpression in Agpat2-/- mice

    PMID:21873652

    Open questions at the time
    • Lipid signaling intermediates responsible for impaired adipogenesis not identified
    • Structural basis for substrate preference unresolved
  4. 2012 High

    AGPAT2 deficiency was shown to impair adipogenesis through altered phospholipid composition—including accumulation of the PPARγ inhibitor cyclic PA—and reduced PI3K/Akt signaling, directly linking the enzyme's lipid products to adipogenic transcriptional programs.

    Evidence Lipidomics, retroviral AGPAT2 rescue, constitutively active Akt expression, and PPARγ agonist treatment in CGL patient-derived cells and 3T3-L1 cells

    PMID:22872237 PMID:23430550

    Open questions at the time
    • Which PA species are the critical signaling intermediates was not resolved
    • CGL-associated mutations characterized for stability but not catalytic mechanism
  5. 2014 High

    Specific PA species (C16:0/18:1 and C18:1/20:4) that accumulate in Agpat2-null liver were shown to directly stimulate hepatic glucose production and resist insulin suppression, providing a molecular mechanism for hepatic insulin resistance in lipodystrophy.

    Evidence Exogenous PA treatment of WT and Agpat2-/- primary hepatocytes with gluconeogenic enzyme expression analysis

    PMID:24425876

    Open questions at the time
    • Receptor or effector through which PA species activate gluconeogenesis not identified
    • In vivo confirmation of PA-driven gluconeogenesis not performed
  6. 2015 High

    Seipin dodecamers were shown to directly bind AGPAT2 and lipin 1 simultaneously, revealing a physical scaffold that organizes the PA biosynthetic pathway at the ER during adipogenesis.

    Evidence Co-immunoprecipitation, atomic force microscopy reconstitution of seipin-AGPAT2-lipin 1 complex

    PMID:25737955

    Open questions at the time
    • Stoichiometry and dynamics of the seipin-AGPAT2 complex in living cells not determined
    • Whether scaffolding is required for lipid droplet biogenesis was unknown
  7. 2016 High

    AGPAT2 was shown to be dispensable for fetal adipose formation but essential for postnatal adipocyte maintenance, with Agpat2-null adipocytes dying within the first postnatal week and lacking caveolae—establishing a continuous requirement for AGPAT2 activity.

    Evidence Light/electron microscopy, lipidomics, and PPARγ rescue in Agpat2-/- mouse tissues and MEFs

    PMID:27408775

    Open questions at the time
    • Mechanism linking AGPAT2 loss to caveolae absence was unclear
    • Whether adipocyte death is apoptotic or necrotic was not defined
  8. 2020 Medium

    GPAT3 was identified as a second seipin-associated enzyme that can simultaneously bind seipin with AGPAT2, expanding the scaffold model to encompass the sequential GPAT→AGPAT steps of PA synthesis.

    Evidence Co-immunoprecipitation and adipogenic differentiation assays in cultured preadipocytes

    PMID:32094408

    Open questions at the time
    • Direct GPAT3-AGPAT2 interaction not demonstrated independently of seipin
    • Functional hierarchy among seipin-bound enzymes not established
  9. 2021 High

    The paradox of PA accumulation despite loss of a PA-generating enzyme was resolved: AGPAT2 directly interacts with and stabilizes CDS1/2, channeling PA into the CDP-DAG pathway; AGPAT2 loss destabilizes CDS enzymes, blocking PA consumption and causing PA buildup.

    Evidence Co-immunoprecipitation, CDS activity assays, lipidomics in cell lines and Agpat2-/- mouse liver

    PMID:34824276

    Open questions at the time
    • Structural basis of the AGPAT2-CDS interaction not determined
    • Whether AGPAT2-CDS complex exists in non-hepatic tissues not confirmed
  10. 2023 High

    Doxycycline-regulated adipose-specific re-expression and subsequent withdrawal in Agpat2-null mice proved that AGPAT2 is continuously required for adipocyte survival in vivo—not just for initial differentiation.

    Evidence Inducible transgenic expression in Agpat2-null mice with adipose mass and leptin measurements upon expression and withdrawal

    PMID:37752957

    Open questions at the time
    • Molecular trigger of adipocyte death upon AGPAT2 withdrawal not identified
    • Whether partial AGPAT2 activity is sufficient for maintenance not tested
  11. 2025 High

    AGPAT2-generated PA was shown to drive ER tubulation by supplying PA to DRP1, which tubulates the ER independently of GTP hydrolysis, establishing a non-canonical structural role for AGPAT2 in ER morphology beyond lipid metabolism.

    Evidence AGPAT2 knockout with FIB-SEM and super-resolution imaging, in vitro reconstitution of DRP1-mediated ER tubulation, lipidomics, LIPIN1 ectopic expression

    PMID:41387688

    Open questions at the time
    • Whether ER morphology changes contribute to the lipodystrophy phenotype is unknown
    • PA-DRP1 binding interface not structurally resolved
    • Relevance to non-adipocyte cell types not explored

Open questions

Synthesis pass · forward-looking unresolved questions
  • Key open questions include the structural basis of AGPAT2's interactions with CDS1/2 and seipin, the identity of PA effectors driving gluconeogenesis, whether AGPAT2-dependent ER tubulation contributes to adipocyte survival or lipid droplet biogenesis, and the molecular trigger of adipocyte death upon AGPAT2 withdrawal.
  • No high-resolution structure of AGPAT2 or its complexes
  • PA sensor/receptor in hepatic gluconeogenesis unidentified
  • Connection between ER tubulation and lipodystrophy phenotype not tested

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0016740 transferase activity 3
Localization
GO:0005783 endoplasmic reticulum 3
Pathway
R-HSA-1430728 Metabolism 5 R-HSA-1643685 Disease 3 R-HSA-1852241 Organelle biogenesis and maintenance 1
Partners
BSCL2CDS1CDS2DNM1LGPAT3LPIN1
Complex memberships
AGPAT2-CDS1/2 complexSeipin-AGPAT2-lipin 1 scaffold complex

Evidence

Reading pass · 14 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2002 AGPAT2 encodes 1-acylglycerol-3-phosphate O-acyltransferase 2, which catalyzes the acylation of lysophosphatidic acid (LPA) to form phosphatidic acid (PA), a key intermediate in the biosynthesis of triacylglycerol and glycerophospholipids; loss-of-function mutations cause congenital generalized lipodystrophy type 1 (CGL1). Genetic linkage mapping, mutation identification, and biochemical characterization of enzyme function Nature genetics High 11967537
2009 In Agpat2-null mice, loss of AGPAT2 leads to severe lipodystrophy affecting both white and brown adipose tissue, with a ~4-fold increase in hepatic de novo fatty acid biosynthesis and markedly increased MOGAT1 (monoacylglycerol acyltransferase isoform 1) expression, indicating activation of an alternative monoacylglycerol pathway for triglyceride biosynthesis in the absence of AGPAT2. Agpat2 knockout mouse model, gene expression analysis, lipid metabolic flux measurements, fat-free diet intervention Cell metabolism High 19187773
2011 Human AGPAT2 and AGPAT1 have similar in vitro substrate specificities for lysophosphatidic acid and acyl-CoA; protein homology modeling with GPAT1 reveals similar tertiary structure; when co-expressed, AGPAT1 and AGPAT2 co-localize to the endoplasmic reticulum; however, restoring AGPAT activity specifically in liver via adenoviral overexpression failed to ameliorate hepatic steatosis in Agpat2-/- mice, indicating that hepatic steatosis is primarily a consequence of insulin resistance and loss of adipose tissue rather than hepatic AGPAT2 deficiency. In vitro enzymatic substrate specificity assays, protein homology modeling, co-immunolocalization, adenoviral overexpression in knockout mice The Journal of biological chemistry High 21873652
2012 AGPAT2 modulates adipogenesis through regulation of the lipome: AGPAT2 deficiency alters levels of phosphatidic acid, lysophosphatidic acid, phosphatidylinositol species, and the PPARγ inhibitor cyclic phosphatidic acid, leading to reduced Akt activation and impaired PI3K/Akt and PPARγ pathway signaling; constitutively active Akt partially restores lipogenesis, and PPARγ agonist pioglitazone partially rescues the adipogenic defect. Muscle-derived multipotent cells from CGL patients, retroviral AGPAT2 rescue, AGPAT2 knockdown and overexpression in 3T3-L1, lipidomics, Akt activation assays, constitutively active Akt expression Diabetes High 22872237
2014 Specific molecular species of phosphatidic acid (PA; C16:0/18:1 and C18:1/20:4), which accumulate in Agpat2-/- mouse livers (~5-fold elevated), enhance hepatic glucose production (HGP) in primary hepatocytes by upregulating gluconeogenic enzymes glucose-6-phosphatase and PEPCK; this PA-induced HGP is suppressed by insulin in wild-type hepatocytes but not in Agpat2-/- hepatocytes, establishing PA as a driver of hepatic insulin resistance in lipodystrophy. Primary hepatocyte cultures, exogenous PA/LPA treatment, gluconeogenic enzyme expression analysis, insulin signaling assays in WT vs Agpat2-/- hepatocytes The Journal of biological chemistry High 24425876
2015 Seipin oligomers (dodecamers) can directly interact with AGPAT2 during adipogenesis, as demonstrated by co-immunoprecipitation and atomic force microscopy; a single seipin complex can simultaneously bind both AGPAT2 and lipin 1 with a defined orientation, physically scaffolding these critical regulators of the PA biosynthetic pathway; stabilizing the seipin-AGPAT2 interaction increases nuclear PPARγ accumulation. Co-immunoprecipitation, immunofluorescence, atomic force microscopy, direct protein interaction reconstitution Molecular metabolism High 25737955
2016 AGPAT2 is essential for postnatal maintenance (but not fetal formation) of white and brown adipose tissue; Agpat2-/- newborn mice have normal adipose tissue mass, but lose it during the first postnatal week due to adipocyte death and inflammatory infiltration; ultrastructurally, Agpat2-/- adipocytes lack caveolae and have abnormal mitochondria and lipid droplets; differentiated Agpat2-/- MEFs have 3-fold increased phosphatidic acid levels and impaired adipogenesis. Light and electron microscopy, immunoblots, qPCR, electrospray ionization tandem mass spectrometry (ESI-MS/MS) phospholipid profiling, PPARγ overexpression rescue in Agpat2-/- MEFs Molecular metabolism High 27408775
2018 AGPAT2 expression is a direct transcriptional target of HIF-1: HIF-1α binds a specific hypoxia response element (HRE) in the AGPAT2 promoter (confirmed by ChIP), and mutation of this HRE abolishes hypoxic activation of the AGPAT2 promoter; AGPAT2 knockdown reduces lipid droplet accumulation and cell viability under hypoxia and increases etoposide sensitivity. siRNA knockdown of HIF-1α, reporter gene assay with AGPAT2 promoter, chromatin immunoprecipitation (ChIP), HRE mutagenesis, siRNA knockdown of AGPAT2 with cell viability and lipid droplet readouts Biochimica et biophysica acta. Molecular and cell biology of lipids High 29908837
2020 Seipin directly interacts with GPAT3 in addition to AGPAT2, and a single seipin complex can simultaneously bind both GPAT3 and AGPAT2; loss of seipin, AGPAT2, or GPAT3 each impairs induction of early adipocyte differentiation markers in cultured cells. Co-immunoprecipitation, adipogenic differentiation assays in cultured preadipocytes, GPAT3-null mouse analysis Scientific reports Medium 32094408
2021 AGPAT2 directly interacts with and stabilizes CDP-diacylglycerol synthases (CDS1/2), forming functional complexes that promote metabolism of PA along the CDP-DAG pathway; AGPAT2 deficiency compromises CDS stability and decreases CDS enzymatic activity in both cell lines and mouse liver, explaining the paradoxical PA accumulation seen in AGPAT2-deficient cells despite AGPAT2 being a PA-generating enzyme. Co-immunoprecipitation, CDS activity assays, lipidomics in cell lines and mouse liver, AGPAT2 knockout models Nature communications High 34824276
2021 In differentiated Agpat2-/- adipocytes, decreased caveolae number is not associated with changes in plasma membrane cholesterol or sphingolipid levels, nor with reduced caveolin-1 or cavin-1 protein levels; however, increased plasma membrane phosphatidylserine content may contribute to the caveolae defect. Plasma membrane purification by ultracentrifugation, electron microscopy, lipidomics (sterol, sphingolipid, phospholipid), immunoblot for caveolae-associated proteins Biochimica et biophysica acta. Molecular basis of disease Medium 33989739
2023 Adipose-tissue-specific re-expression of human AGPAT2 in Agpat2-null mice (regulated by doxycycline) resulted in partial regeneration of both white and brown adipose tissue; turning off AGPAT2 expression caused total loss of regenerated adipose tissue, demonstrating that AGPAT2 is essential for adipocyte differentiation in vivo and that adipocytes require continuous AGPAT2 activity for survival. Doxycycline-regulated adipose-tissue-specific transgenic expression in Agpat2-null mice, adipose tissue mass measurement, ex vivo differentiation of stromal vascular fraction cells, leptin secretion measurement iScience High 37752957
2025 AGPAT2-generated phosphatidic acid (PA) drives ER tubulation by interacting with and supplying PA to the PA-binding dynamin-related GTPase DRP1, which subsequently tubulates the ER independently of GTP hydrolysis and oligomerization; AGPAT2 knockout shifts ER morphology from tubules to sheets, and ectopic expression of PA phosphatase LIPIN1 similarly converts ER tubules to sheets; AGPAT2 was identified by screening 18 PA-generating enzymes for effects on ER morphology. Gene knockout, 3D structural analysis by FIB-SEM, super-resolution microscopy, lipidomics, AlphaFold structural modeling, in vitro reconstitution of ER tubulation, in vitro AGPAT2 activity assays, LIPIN1 ectopic expression Nature communications High 41387688
2012 Both the p.Cys48Arg and p.Leu228Pro AGPAT2 mutant proteins show significantly reduced protein levels compared to wild-type AGPAT2 despite equivalent mRNA levels, and fail to rescue adipogenesis in AGPAT2-deficient preadipocytes, indicating these mutations cause loss of function primarily through protein instability rather than mRNA reduction. Expression of wild-type and mutant AGPAT2 in AGPAT2-deficient preadipocyte cell lines, mRNA and protein quantification, adipogenic rescue assay JIMD reports Medium 23430550

Source papers

Stage 0 corpus · 44 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2002 AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34. Nature genetics 394 11967537
2009 Molecular mechanisms of hepatic steatosis and insulin resistance in the AGPAT2-deficient mouse model of congenital generalized lipodystrophy. Cell metabolism 185 19187773
2003 Phenotypic heterogeneity in body fat distribution in patients with congenital generalized lipodystrophy caused by mutations in the AGPAT2 or seipin genes. The Journal of clinical endocrinology and metabolism 114 14602785
2015 Seipin oligomers can interact directly with AGPAT2 and lipin 1, physically scaffolding critical regulators of adipogenesis. Molecular metabolism 73 25737955
2011 Human 1-acylglycerol-3-phosphate O-acyltransferase isoforms 1 and 2: biochemical characterization and inability to rescue hepatic steatosis in Agpat2(-/-) gene lipodystrophic mice. The Journal of biological chemistry 71 21873652
2018 Expression of AGPAT2, an enzyme involved in the glycerophospholipid/triacylglycerol biosynthesis pathway, is directly regulated by HIF-1 and promotes survival and etoposide resistance of cancer cells under hypoxia. Biochimica et biophysica acta. Molecular and cell biology of lipids 68 29908837
2003 Prevalence of mutations in AGPAT2 among human lipodystrophies. Diabetes 66 12765973
2004 Mutations in Gng3lg and AGPAT2 in Berardinelli-Seip congenital lipodystrophy and Brunzell syndrome: phenotype variability suggests important modifier effects. The Journal of clinical endocrinology and metabolism 50 15181077
2012 Alterations in lipid signaling underlie lipodystrophy secondary to AGPAT2 mutations. Diabetes 49 22872237
2013 Leptin ameliorates insulin resistance and hepatic steatosis in Agpat2-/- lipodystrophic mice independent of hepatocyte leptin receptors. Journal of lipid research 45 24293639
2005 Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors. Oncogene 41 15735676
2016 AGPAT2 is essential for postnatal development and maintenance of white and brown adipose tissue. Molecular metabolism 37 27408775
2009 Novel mutations of the BSCL2 and AGPAT2 genes in 10 families with Berardinelli-Seip congenital generalized lipodystrophy syndrome. Clinical endocrinology 36 19226263
2021 AGPAT2 interaction with CDP-diacylglycerol synthases promotes the flux of fatty acids through the CDP-diacylglycerol pathway. Nature communications 35 34824276
2004 Mutations in the seipin and AGPAT2 genes clustering in consanguineous families with Berardinelli-Seip congenital lipodystrophy from two separate geographical regions of Brazil. The Journal of clinical endocrinology and metabolism 31 14715872
2010 Pathology of congenital generalized lipodystrophy in Agpat2-/- mice. Veterinary pathology 27 21051554
2020 Oligomers of the lipodystrophy protein seipin may co-ordinate GPAT3 and AGPAT2 enzymes to facilitate adipocyte differentiation. Scientific reports 23 32094408
2016 Mogat1 deletion does not ameliorate hepatic steatosis in lipodystrophic (Agpat2-/-) or obese (ob/ob) mice. Journal of lipid research 22 26880786
2005 Phenotypic heterogeneity in biochemical parameters correlates with mutations in AGPAT2 or Seipin genes among Berardinelli-Seip congenital lipodystrophy patients. Journal of inherited metabolic disease 22 16435205
2020 Congenital Generalized Lipoatrophy (Berardinelli-Seip Syndrome) Type 1: Description of Novel AGPAT2 Homozygous Variants Showing the Highly Heterogeneous Presentation of the Disease. Frontiers in endocrinology 20 32117065
2015 AGPAT2 deficiency impairs adipogenic differentiation in primary cultured preadipocytes in a non-autophagy or apoptosis dependent mechanism. Biochemical and biophysical research communications 19 26417690
2014 Hepatic gluconeogenesis is enhanced by phosphatidic acid which remains uninhibited by insulin in lipodystrophic Agpat2-/- mice. The Journal of biological chemistry 18 24425876
2014 Divergent metabolic phenotype between two sisters with congenital generalized lipodystrophy due to double AGPAT2 homozygous mutations. a clinical, genetic and in silico study. PloS one 16 24498038
2012 Identification of a novel nonsense mutation and a missense substitution in the AGPAT2 gene causing congenital generalized lipodystrophy type 1. European journal of medical genetics 13 22902344
2012 Identification and Characterisation of a Novel Pathogenic Mutation in the Human Lipodystrophy Gene AGPAT2 : C48R: A Novel Mutation in AGPAT2. JIMD reports 11 23430550
2018 Identifying Lysophosphatidic Acid Acyltransferase β (LPAAT-β) as the Target of a Nanomolar Angiogenesis Inhibitor from a Phenotypic Screen Using the Polypharmacology Browser PPB2. ChemMedChem 10 30520265
2018 Further delineation of AGPAT2 and BSCL2 related congenital generalized lipodystrophy in young infants. European journal of medical genetics 8 30266686
2018 A Single Complex Agpat2 Allele in a Patient With Partial Lipodystrophy. Frontiers in physiology 8 30319454
2021 Decreased caveolae in AGPAT2 lacking adipocytes is independent of changes in cholesterol or sphingolipid levels: A whole cell and plasma membrane lipidomic analysis of adipogenesis. Biochimica et biophysica acta. Molecular basis of disease 7 33989739
2020 Leu124Serfs*26, a novel AGPAT2 mutation in congenital generalized lipodystrophy with early cardiovascular complications. Diabetology & metabolic syndrome 7 32280377
2017 Activation of Sphingolipid Pathway in the Livers of Lipodystrophic Agpat2 Mice. Journal of the Endocrine Society 7 29264548
2011 Description of an AGPAT2 pathologic allelic variant in a 54-year-old Caucasian woman with Berardinelli-Seip syndrome. Acta diabetologica 7 21744063
2023 Transcriptional Inhibition of AGPAT2 Induces Abnormal Lipid Metabolism and Oxidative Stress in the Liver of Nile Tilapia Oreochromis niloticus. Antioxidants (Basel, Switzerland) 5 36978948
2023 Regulated adipose tissue-specific expression of human AGPAT2 in lipodystrophic Agpat2-null mice results in regeneration of adipose tissue. iScience 5 37752957
2018 A Patient with Berardinelli-Seip Syndrome, Novel AGPAT2 Splicesite Mutation and Concomitant Development of Non-diabetic Polyneuropathy. Journal of clinical research in pediatric endocrinology 5 30563316
2013 AGPAT2 gene mutation in a child with Berardinelli-Seip congenital lipodystrophy syndrome. Annales d'endocrinologie 5 23337016
2023 Lipodystrophic gene Agpat2 deficiency aggravates hyperlipidemia and atherosclerosis in Ldlr-/- mice. Biochimica et biophysica acta. Molecular basis of disease 4 37591406
2023 Adipose-specific overexpression of human AGPAT2 in mice causes increased adiposity and mild hepatic dysfunction. iScience 3 38274405
2025 The Role of the AGPAT2 Gene in Adipose Tissue Biology and Congenital Generalized Lipodystrophy Pathophysiology. International journal of molecular sciences 2 40508223
2024 Regulated regeneration of adipose tissue in lipodystrophic Agpat2-null mice partially ameliorates hepatic steatosis. iScience 2 38623324
2024 LncRNA ENSGALG00000021686 regulates fat metabolism in chicken hepatocytes via miR-146b/AGPAT2 pathway. Animal genetics 1 38369771
2025 A case of familial hypertriglyceridemia associated with a novel heterozygous AGPAT2 mutation. Annals of medicine and surgery (2012) 0 40212223
2025 AGPAT2 acts at the crossroads of lipid biosynthesis and DRP1-mediated ER morphogenesis. Nature communications 0 41387688
2020 [Identification of a novel AGPAT2 variant in a Chinese patient with congenital generalized lipodystrophy type 1]. Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics 0 32924125